You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment653% Female63%% WhiteN/A
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-INT-1Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)72
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
- 2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2021-4743 : Machine Learning Approaches to Predicting Treatment Outcomes in Alzheimer's Disease
- 2020-4448 : Reanalysis of Alzheimer?s Disease Clinical Trials Using Longitudinal Latent Trait Models
- 2016-0765 : Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The ?Optimising the Analysis of Cognition? Collaboration